Fusion Pharmaceuticals Inc.
Fusion Pharmaceuticals Inc. (FUSN): 9 pipeline candidates · ~23 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
22.6 months
D/E 0.34 · 0% dilution
Lead: Phase 2
9 candidates
N/A
N/A
A transparent, data-derived signal for Fusion Pharmaceuticals Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$29.1M
Quarterly Burn
$27.3M
Runway
22.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| [111in]-fpi-1547 | Phase 1 |
| [225ac]-fpi-1434 injection multi-dose | Phase 1 |
| [225ac]-fpi-1434 injection single-dose | Phase 1 |
| fpi-1175 infusion | Phase 1 |
| fpi-1434 | Phase 1 |
| fpi-1966 | Phase 1 |
| fpi-2059 | Phase 2 |
| fpi-2068 | Phase 2 |
| fpi-2265 | Phase 2 |
Frequently asked questions
How many drug candidates are in Fusion Pharmaceuticals Inc.'s pipeline?
Fusion Pharmaceuticals Inc. (FUSN) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Fusion Pharmaceuticals Inc.'s lead drug candidate?
Fusion Pharmaceuticals Inc.'s most advanced tracked candidate is [111in]-fpi-1547 (Phase 1) for Advanced Solid Tumours.
What is Fusion Pharmaceuticals Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Fusion Pharmaceuticals Inc. has approximately 22.6 months of cash runway.
Get the full picture on Fusion Pharmaceuticals Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.